Introduction: JDRF’s Role in Reshaping Type 1 Diabetes Care Worldwide

The Juvenile Diabetes Research Foundation (JDRF) stands as the world’s largest nonprofit funder of Type 1 Diabetes (T1D) research. Since its founding in 1970, JDRF has driven a paradigm shift in how T1D is understood, managed, and ultimately pursued toward a cure. Its global initiatives—spanning basic science, translational research, clinical trials, advocacy, and patient education—have directly influenced the standards of care adopted by endocrinologists, diabetes educators, and health systems across the developed and developing world.

Today’s T1D management is unrecognisable from the era of sole reliance on multiple daily injections and urine glucose testing. The advent of continuous glucose monitoring (CGM), hybrid closed-loop systems, and advanced insulin analogs can be traced, in significant part, to JDRF-supported research networks. This article examines how JDRF’s strategic funding and collaborative framework have accelerated innovations, embedded evidence into clinical guidelines, and empowered patients to achieve tighter glycemic control while reducing the burden of daily disease management.

JDRF’s Research Initiatives: A Global Engine for Innovation

JDRF’s research portfolio is structured around a clear mission: to discover, develop, and deliver preventions, treatments, and cures for T1D. The foundation invests more than $100 million annually into research, deploying funds through targeted programs such as the JDRF Research Network, the European Consortium for the Cure of Type 1 Diabetes, and the JDRF T1D Fund (a venture philanthropy arm that bridges the gap between academic discoveries and commercial development).

These initiatives are not siloed. JDRF actively forges partnerships with leading academic institutions—including the University of Cambridge, the Diabetes Research Institute at the University of Miami, and the Benaroya Research Institute—and with industry players like Dexcom, Medtronic, and Tandem Diabetes Care. The result is a coordinated pipeline that moves promising concepts from bench to bedside faster than traditional funding models allow.

Key areas of JDRF-funded research include:

  • Beta cell preservation and regeneration: Trials exploring anti-CD3 monoclonal antibodies (e.g., teplizumab) and low-dose anti-thymocyte globulin to delay disease onset and preserve residual insulin production.
  • Cell replacement therapies: Investment in encapsulation technologies and stem-cell-derived islet progenitors, aiming to create a renewable source of insulin-producing cells without lifelong immunosuppression.
  • Artificial pancreas systems: Early-stage funding for algorithm-based closed-loop control, leading to the FDA clearance of the first hybrid closed-loop system (MiniMed 670G) in 2016.
  • Immune modulation and tolerance induction: Support for antigen-specific immunotherapy and regulatory T-cell therapy to halt autoimmune destruction without general immune suppression.
  • Precision medicine: Genomic and proteomic studies to identify biomarkers that predict disease progression and treatment response.

These research streams have not only produced breakthroughs but also established a rigorous evidence base that informs how clinicians and health systems approach T1D management.

Transforming T1D Management Standards: From Reactive to Proactive Care

JDRF’s greatest influence on T1D management standards lies in driving the clinical adoption of continuous glucose monitoring (CGM). Before JDRF launched its “CGM for All” advocacy campaign, CGMs were viewed as niche devices for patients with extreme glycemic variability. Through landmark trials such as the JDRF CGM Study Group’s pivotal 2008 study, the foundation demonstrated that CGM use significantly lowered HbA1c across all age groups regardless of baseline control. This evidence directly influenced the American Diabetes Association’s (ADA) Standards of Medical Care, which now recommend CGM for all individuals with T1D who are able to use the devices safely.

Beyond CGM, JDRF-funded research helped validate the clinical benefit of insulin pump therapy over multiple daily injections, particularly in reducing severe hypoglycemia in children. The foundation also played a key role in establishing glycemic targets that are now embedded in international guidelines: a time-in-range (TIR) of 70–180 mg/dL for at least 70% of the day, and a goal of less than 4% of time below 70 mg/dL.

How JDRF Accelerated Regulatory Approval of Hybrid Closed-Loop Systems

The journey from concept to approved hybrid closed-loop (HCL) technology is a direct case study of JDRF’s impact. In 2013, JDRF formed the Artificial Pancreas Consortium, connecting academic researchers (e.g., Dr. Roman Hovorka at Cambridge) with manufacturers. The consortium ran a series of outpatient trials that generated the safety and efficacy data required for FDA submission. When the MiniMed 670G received FDA approval in 2016, JDRF’s role was explicitly acknowledged by the agency. Today, Tandem’s Control-IQ and Medtronic’s 780G algorithms—both built on algorithms developed in JDRF-funded labs—are considered standard of care, enabling users to maintain TIR above 70% while reducing hypoglycemia by 50–70%.

Redefining Hypoglycemia Prevention and Glucose Variability

JDRF also invested heavily in standardizing the measurement and clinical importance of glucose variability. The foundation sponsored the International Consensus on Use of Continuous Glucose Monitoring, which led to the standardized reporting of metrics such as coefficient of variation (CV) and TIR. These metrics are now part of the 2023 ADA Standards of Care, shifting the focus from HbA1c alone to a multidimensional view of glycemic control that prioritizes stability and time in range.

Specific Technological Breakthroughs Accelerated by JDRF

Continuous Glucose Monitoring (CGM)

JDRF’s investment in CGM was catalytic. In 2006, the foundation committed $10 million to the development of next-generation CGM sensors, leading to the Dexcom G4 and later G6 systems—the first CGMs that did not require fingerstick calibration. The foundation also funded head-to-head comparisons of CGM platforms, which helped providers choose the right device for their patients based on accuracy, wear time, and data integration.

Today, CGM is no longer an add-on technology; it is the core of T1D management. JDRF’s work facilitated Medicare coverage for CGM in 2017 and subsequently for all people with T1D. Expanded Medicare coverage for CGM is a direct legacy of JDRF’s advocacy and data-driven policy engagement.

Automated Insulin Delivery (AID) Systems

Beyond the artificial pancreas, JDRF has funded research on simpler AID systems known as predictive low-glucose suspend (PLGS) and insulin-only closed-loop. The PLGS feature, now standard in many pumps, was first shown to reduce nocturnal hypoglycemia in the JDRF-funded PLGS trial published in Diabetes Care. This technology prevented an estimated 40% of nighttime low events.

JDRF also pioneered the “bionic pancreas” concept by supporting the work of Dr. Edward Damiano at Boston University. The iLet Bionic Pancreas, which received FDA clearance in 2023, uses a self-learning algorithm that adjusts insulin delivery based on initial user weight alone, eliminating the need for carbohydrate counting—a major barrier to pump initiation. The trial data showing superiority over standard care were made possible through grants from JDRF’s Type 1 Diabetes Fund.

Advanced Insulin Analogs and Smart Insulin

JDRF provides early-stage funding for novel insulin formulations, including ultra-rapid-acting insulins (e.g., Fiasp) and once-weekly basal insulins. The foundation also supports the development of “smart” insulin—glucose-responsive insulin that circulates in the body and activates only when blood sugar rises. While still experimental, JDRF’s portfolio includes several proof-of-concept studies using polymer-based insulin conjugates and enzyme-sensitive delivery systems. If successful, smart insulin could dramatically simplify T1D management to a single shot every few days with no risk of severe hypoglycemia.

Policy Advocacy and Education: Shaping the Care Landscape

JDRF’s impact extends beyond the lab and clinic. The foundation runs one of the most effective grassroots advocacy networks in chronic disease. Each year, thousands of JDRF volunteers participate in “JDRF Advocacy Day” on Capitol Hill and in national parliaments to push for legislation that supports T1D research funding, insurance coverage for CGM and pumps, and access to affordable insulin.

Key policy successes include:

  • The Special Diabetes Program (SDP) in the United States, which provides $150 million annually for T1D research at the National Institutes of Health (NIH). JDRF’s lobbying was instrumental in reauthorizing SDP in 2020.
  • Passage of state-level laws in 22 U.S. states capping out-of-pocket costs for insulin at $25–35 per month, following JDRF-led “Insulin for All” campaigns.
  • Inclusion of CGM under the UK’s National Health Service (NHS) prescribing guidelines for children and adults with T1D, after JDRF UK submitted evidence from the SOLVE and COMISAIR trials.

Patient and Provider Education

JDRF’s educational resources—including the T1D Toolkit, online webinars, and the “TypeOneNation” peer support network—ensure that management standards are implemented at the individual level. The foundation publishes consensus statements on topics such as school diabetes management, exercise guidelines, and technology use in preschoolers, which are referenced by pediatric endocrinologists worldwide.

Global Reach: Extending Standards to Underserved Regions

JDRF’s International Research Program partners with organizations such as the World Health Organization and the International Diabetes Federation to adapt management standards for low-resource settings. For example, JDRF funded a trial in sub-Saharan Africa that demonstrated the feasibility of using flash glucose monitoring (Freestyle Libre) in areas without reliable electricity, leading to revised local guidelines. This work underscores JDRF’s commitment that improved management standards should benefit all people with T1D, not only those in high-income nations.

Future Directions: Toward a Cure and Beyond

While JDRF has already transformed management, its “100-Year Vision” aims to eliminate the burden of T1D entirely by the foundation’s centenary in 2070. Current research priorities include:

  • Gene editing: Using CRISPR-based approaches to correct the autoimmune defect or to program insulin production from other cell types. JDRF has funded the development of “universal” donor islets that can be transplanted without immunosuppression.
  • Immune reset: Combination immunotherapies that re-establish tolerance to beta cells. A Phase II trial of Linsitinib (an IGF-1 receptor inhibitor) supported by JDRF showed preservation of C-peptide levels for up to 12 months.
  • Artificial intelligence in diabetes care: Algorithms that predict hypoglycemia 30–60 minutes ahead and adjust therapy proactively. JDRF’s AI for Diabetes initiative funds machine learning models that integrate CGM, activity tracker, and meal data to personalize treatment.
  • Stem cell-derived beta cells: Via the JDRF-supported Betalogics collaboration, researchers have developed encapsulated stem-cell islets that survive in the body for over 18 months without immunosuppression. Clinical trials are expected to begin in 2025.

Each of these directions carries the potential to redefine management standards yet again—moving from “manage the disease” to “reverse the disease.” JDRF’s model of funding high-risk, high-reward research while simultaneously advocating for access to existing technologies ensures that today’s breakthroughs become tomorrow’s standard of care.

“JDRF has been the single most important driver of translational research in Type 1 Diabetes over the past three decades. The management standards we use today were shaped, proven, and disseminated with JDRF’s support.” — Dr. Anne Peters, Director of Clinical Diabetes Programs at the University of Southern California

Conclusion: A Legacy of Raising the Bar for T1D Care

The impact of JDRF’s global research initiatives on T1D management standards is neither accidental nor temporary. Through strategic funding of CGM and AID technologies, rigorous clinical trials that inform guidelines, relentless policy advocacy, and a pipeline of curative therapies, JDRF has elevated what is possible for people with T1D. A teenager diagnosed today can expect to maintain an HbA1c below 7% with minimal severe hypoglycemia, access advanced devices, and look forward to a future where T1D may no longer require constant vigilance.

As standards continue to evolve—driven by JDRF’s ongoing investment in immunotherapy, smart insulin, and cell replacement—the foundation remains the linchpin connecting research discovery with daily reality. For clinicians, researchers, and patients alike, JDRF’s work is not just influential; it is foundational.

Explore more about JDRF’s current research initiatives at JDRF.org/research and the ADA’s latest standards of care here.